Shane Brown has joined GT Medical Technologies as its chief commercial officer. In this role, he will oversee all aspects of the company’s commercial strategies to drive growth and adoption of …
GT Medical Technologies, Inc. announced today it was named Company of the Year for Health Products & Services in the 2022 American Business Awards. This honor acknowledges GT Medical Technologies’ pioneering technology GammaTile® Therapy, FDA-cleared for treating newly diagnosed malignant and recurrent brain tumors.
GT Medical Technologies, Inc. announced today that new data on the company’s innovative GammaTile Therapy for patients with operable brain tumors will be presented via an oral, live presentation at the 2022 American Association of Neurological Surgeons (AANS) Annual Scientific Meeting in Philadelphia, PA. The abstract will provide the first report of clinical outcomes for recurrent glioblastoma patients treated with FDA-cleared GammaTile Therapy.
GT Medical Technologies Inc., creators of GammaTile Therapy, a Surgically Targeted Radiation Treatment for operable brain tumors, today announced its 2021 roster of ELITE Distinguished Brain Tumor Specialists that have completed 10 or more GammaTile Therapy procedures in 2021.
Drs. Ondrej Choutka, MD, a neurosurgeon, and Lindsay Sales, MD, a radiation oncologist at Saint Alphonsus Regional Medical Center in Boise, have become the first doctors in the Pacific Northwest to utilize a new treatment for brain tumors. They implanted the FDA-cleared GammaTile therapy in a 44-year-old patient with a malignant brain tumor.
Surgeons at Henry Ford Health System have treated a patient with a recurrent brain tumor by delivering a dose of radiation directly to the cancer inside the brain, a novel approach that could delay or prevent future tumor cells from regrowing.
Mayfield Brain & Spine, the region’s premier neurosurgery practice, announced that the first patients have been enrolled in a new clinical trial to investigate GammaTile® targeted therapy to treat newly diagnosed metastatic brain tumors.
GT Medical Technologies, Inc. today announced it was named a winner of the Innovator of the Year in the small company category at the 2021 Governor’s Celebration of Innovation, presented live on stage by the Arizona Technology Council and the Arizona Commerce Authority on October 13.
GT Medical Technologies, Inc. today announced it is presenting clinical data in two oral presentations on the company’s breakthrough GammaTile® Therapy for patients with brain tumors at the 2021 American Association of Neurological Surgeons (AANS) Annual Scientific Meeting.
This press release announces a trial collaboration between Novocure and GT Medical Technologies to develop Tumor Treating Fields (TTFields) together with GammaTile Therapy for the treatment of recurrent GBMs. Tumor Treating Fields are electric fields that disrupt cancer cell division. The study will evaluate the effectiveness and safety of adjuvantly using TTFields prior to resection + GammaTile, with progression free survival (PFS) for the ITT population being the primary endpoint.
